O. V. Reshetko

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis

Brad H. Rovin, Neil Solomons, William F. Pendergraft et al. · Kidney International · 2018 · 304 citations

Medicine, Nephrology, Pharmacology +8

Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)

Arthur Kavanaugh, Joel M. Kremer, L Ponce et al. · Annals of the Rheumatic Diseases · 2016 · 230 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

Sean D. Pokorney, Jonathan P. Piccini, Susanna R. Stevens et al. · Journal of the American Heart Association · 2016 · 200 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

Thomas M. File, Donald E. Low, Paul B. Eckburg et al. · Journal of Antimicrobial Chemotherapy · 2011 · 196 citations · Full text

Medicine, Infectious Diseases, Pharmacology +13